Quarterly report pursuant to Section 13 or 15(d)

REVENUES

v3.24.2.u1
REVENUES
 6 Months Ended
Jun. 30, 2024
Revenue from Contract with Customer [Abstract]  
REVENUES

 NOTE 9 – REVENUES

 

Disaggregation of Net Revenues

 

The Company’s net product revenues are summarized below: 

                 
   

Three months ended 

June 30, 

  
    2024   2023  
Zembrace Symtouch   $ 1,727   $ —  
Tosymra     481     —  
Total product revenues   $ 2,208   $ —  

                 
   

Six months ended 

June 30, 

  
    2024   2023  
Zembrace Symtouch   $ 3,574   $ —  
Tosymra     1,116     —  
Total product revenues   $ 4,690   $ —  

 

Gross-to-Net Sales Accruals

 

We record gross-to-net sales accruals for chargebacks, rebates, sales and other discounts, and product returns, which are all customary to the pharmaceutical industry.

 

Our provision for gross-to-net allowances was $4.3 million at June 30, 2024, $0.6 million of which was recorded as a reduction to accounts receivable and $3.7 million recorded as a component of accrued expenses.